Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT ID: NCT05650229
Last Updated: 2025-10-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
180 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-12-13
Study Completion Date
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis
NCT02487407
Amyotrophic Lateral Sclerosis
COMPLETED
PHASE2
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT05747924
FSHD
FSHD1
FSHD2
+24 more
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592
Amyotrophic Lateral Sclerosis (ALS)
Mutation in the Superoxide Dismutase-1 (SOD1) Gene
RECRUITING
PHASE1
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
NCT05053035
Amyotrophic Lateral Sclerosis
TERMINATED
PHASE2
A Dose-escalating Clinical Trial With KH176
NCT02544217
MELAS
LHON
Leigh Syndrome
+2 more
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The FALCON study is investigating whether the study medicine, KL1333, improves fatigue levels and physical abilities of people living with mitochondrial disease. The investigators are also evaluating the tolerability of the study medicine. For this study, the effects of KL1333 are compared with those from a placebo (a pill that looks like the study medicine but contains no active medicine). The study medicine (or placebo) is a tablet that is taken twice daily during the treatment period of 48 weeks.
Participation in the FALCON study is divided into 3 parts:
* Screening and baseline: 8-12 weeks
* Treatment: 48 weeks
* Safety follow-up: 5 weeks Total duration: 61 - 65 weeks
Patients who complete the screening phase and are enrolled in the study are randomly assigned to receive either the study medicine (KL1333) or placebo (no active medication). Patients are more likely to receive the study medication than placebo (for every five people who take part, three receive KL1333 and two receive placebo). Neither the participants nor the study team know who is receiving the study medicine or placebo and participants are not able to change which treatment they are assigned.
Participation in the FALCON study is divided into 3 parts:
* Screening and baseline: 8-12 weeks
* Treatment: 48 weeks
* Safety follow-up: 5 weeks Total duration: 61 - 65 weeks
Patients who complete the screening phase and are enrolled in the study are randomly assigned to receive either the study medicine (KL1333) or placebo (no active medication). Patients are more likely to receive the study medication than placebo (for every five people who take part, three receive KL1333 and two receive placebo). Neither the participants nor the study team know who is receiving the study medicine or placebo and participants are not able to change which treatment they are assigned.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Primary Mitochondrial Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KL1333
Twice daily
Group Type
EXPERIMENTAL
KL1333
Intervention Type
DRUG
Twice daily
Matching Placebo
Twice daily
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KL1333
Twice daily
Intervention Type
DRUG
Placebo
Twice daily
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or older.
* A confirmed PMD diagnosis caused by a known pathogenic gene mutation or deletion of the mitochondrial genome (category 6 of the International Classification of Inborn Metabolic Disorders \[ICIMD\])12 according to American College of Medical Genetics (ACMG)/Association of Molecular Pathology (AMP) criteria1, with multisystemic disease expressions, including:
1. m.3243A\>G associated MELAS-MIDD spectrum disorders,
2. single large scale mtDNA deletion associated KSS-CPEO spectrum disorders,
3. other multisystemic mtDNA-related disease (including MERRF).
* Presence of chronic mitochondrial fatigue:
* History of mitochondrial fatigue for at least 3 months prior to the Screening Visit AND
* Presence of at least moderate level of fatigue, assessed by PROMIS® Fatigue PMD Short form raw score ≥ 27 at Screening and Baseline
* Presence of mitochondrial myopathy defined as:
* Myopathy (proximal muscle weakness), NMDAS Section III Clinical Assessment, item 5 score ≥ 1, which reads: "minimal reduction in hip flexion and/or shoulder abduction only (e.g. MRC 4+/5)". For the inclusion only hip flexion, but not shoulder abduction, should be taken into account. AND / OR
* Exercise Tolerance: NMDAS Section I, item 9 score ≥ 1, which reads: "unlimited on flat - symptomatic on inclines or stairs".
* Patients must be able to perform at least 2 repetitions and the maximal capacity must not exceed 17 repetitions in males or 16 repetitions in females in a 30s STS test at screening.
* Clinically stable, apart from symptoms associated with the diagnosis of mitochondrial disease, at Screening and Baseline, as determined by medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations at Screening, as assessed by the investigator.
* The patient is willing and able to attend study appointments within the specified time windows.
* Willingness and ability to complete electronic PROs.
* Willingness to maintain a stable diet during the Screening and study periods.
* Patients who take any mitochondrial disease-focused vitamins or supplemental therapies, including coenzyme Q10 (CoQ10), niacin/nicotinamide (vitamin B3), and L-arginine, has been on a stable dose regimen of these for 3 months prior to randomisation and intends to stay on a stable dose for the duration of the study period.
* Willingness to suspend treatment with idebenone during the study.
* Female patient is not pregnant and at least one of the following conditions apply:
1. Not a woman of childbearing potential (WOCBP)
2. WOCBP must agree not to try and become pregnant and use a highly effective method of contraception from the time of informed consent through at least 36 days (\~5 half-lives of KL1333 plus 30 days) after the last dose of investigational medicinal product (IMP) administration.
* Male patients with female partner(s) of childbearing potential must agree to use a male condom in addition to using highly effective contraception throughout the treatment period and for 96 days after the last dose of IMP administration. The requirement to use a male condom also applies to male patients with a pregnant or breastfeeding partner.
* Female patients must agree not to breastfeed starting at Screening and throughout the study period and for 36 days after the last dose of IMP administration.
* Female patients must agree to not donate ova throughout the study period and for 36 days after the last dose of IMP administration, and male patients must agree to not donate sperm throughout the study period and for 96 days after the last dose of IMP administration.
* A confirmed PMD diagnosis caused by a known pathogenic gene mutation or deletion of the mitochondrial genome (category 6 of the International Classification of Inborn Metabolic Disorders \[ICIMD\])12 according to American College of Medical Genetics (ACMG)/Association of Molecular Pathology (AMP) criteria1, with multisystemic disease expressions, including:
1. m.3243A\>G associated MELAS-MIDD spectrum disorders,
2. single large scale mtDNA deletion associated KSS-CPEO spectrum disorders,
3. other multisystemic mtDNA-related disease (including MERRF).
* Presence of chronic mitochondrial fatigue:
* History of mitochondrial fatigue for at least 3 months prior to the Screening Visit AND
* Presence of at least moderate level of fatigue, assessed by PROMIS® Fatigue PMD Short form raw score ≥ 27 at Screening and Baseline
* Presence of mitochondrial myopathy defined as:
* Myopathy (proximal muscle weakness), NMDAS Section III Clinical Assessment, item 5 score ≥ 1, which reads: "minimal reduction in hip flexion and/or shoulder abduction only (e.g. MRC 4+/5)". For the inclusion only hip flexion, but not shoulder abduction, should be taken into account. AND / OR
* Exercise Tolerance: NMDAS Section I, item 9 score ≥ 1, which reads: "unlimited on flat - symptomatic on inclines or stairs".
* Patients must be able to perform at least 2 repetitions and the maximal capacity must not exceed 17 repetitions in males or 16 repetitions in females in a 30s STS test at screening.
* Clinically stable, apart from symptoms associated with the diagnosis of mitochondrial disease, at Screening and Baseline, as determined by medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations at Screening, as assessed by the investigator.
* The patient is willing and able to attend study appointments within the specified time windows.
* Willingness and ability to complete electronic PROs.
* Willingness to maintain a stable diet during the Screening and study periods.
* Patients who take any mitochondrial disease-focused vitamins or supplemental therapies, including coenzyme Q10 (CoQ10), niacin/nicotinamide (vitamin B3), and L-arginine, has been on a stable dose regimen of these for 3 months prior to randomisation and intends to stay on a stable dose for the duration of the study period.
* Willingness to suspend treatment with idebenone during the study.
* Female patient is not pregnant and at least one of the following conditions apply:
1. Not a woman of childbearing potential (WOCBP)
2. WOCBP must agree not to try and become pregnant and use a highly effective method of contraception from the time of informed consent through at least 36 days (\~5 half-lives of KL1333 plus 30 days) after the last dose of investigational medicinal product (IMP) administration.
* Male patients with female partner(s) of childbearing potential must agree to use a male condom in addition to using highly effective contraception throughout the treatment period and for 96 days after the last dose of IMP administration. The requirement to use a male condom also applies to male patients with a pregnant or breastfeeding partner.
* Female patients must agree not to breastfeed starting at Screening and throughout the study period and for 36 days after the last dose of IMP administration.
* Female patients must agree to not donate ova throughout the study period and for 36 days after the last dose of IMP administration, and male patients must agree to not donate sperm throughout the study period and for 96 days after the last dose of IMP administration.
Exclusion Criteria
* Primary mitochondrial disease with predominant neurodegenerative phenotypes, such as, but not limited to, Leigh syndrome, Leber hereditary optic neuropathy (LHON) and Neuropathy ataxia-retinitis pigmentosa syndrome (NARP).
* Primary mitochondrial disease nuclear DNA mutations or mutations causing mtDNA destabilisation. Genetic mtDNA variants of uncertain significance, likely pathogenic, or pathogenic mutations with degrees of heteroplasmy below what can be considered to definitely cause PMD.
* General fatigue or muscle weakness due to causes other than mitochondrial disease, in the opinion of the investigator.
* Significant cardiovascular disease (e.g., sustained or symptomatic arrhythmia; dilated heart chambers or reduced function; Mobitz II atrioventricular block or greater) OR abnormal ECG that is clinically significant, as determined by the investigator. Any QTcF \> 450 msec for male patients and \> 470 msec for female patients is exclusionary. In the case of an exclusionary QTcF, the ECG can be repeated twice and the average of 3 QTcF intervals should be used to determine the QTcF eligibility.
* Recent history of unstable disease, inadequately controlled neurological manifestations or not recovered from stroke-like episodes including but not limited to:
1. stroke-like episodes within the last 6 months
2. more than 1 seizure/month within the last 6 months
3. hospitalised for Status Epilepticus within the last 6 months
4. more than 4 days of migraine episodes/month within the last 6 months
* History of inflammatory bowel disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes. Gastroesophageal reflux disease diagnosed by objective endoscopic or radiographic means, and clinically symptomatic at any point over the last 6 months.
* The patient has one or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the Screening Visit, that are of potential risk to the patient's safety, or the patient has, at the Screening Visit:
* estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \<30 mL/min/1.73 m2
* a serum total bilirubin value \> 1.5 times the upper limit of the reference range unless elevation is related to Gilbert's syndrome and the investigator can rule out any underlying liver dysfunction based on other tests, the patient has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
* a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \> 2 times the upper limit of the reference range. Values between 2 and 3 times the upper limit of the reference range may be allowed if concomitant to elevation in creatine kinase as long as the investigator can rule out any underlying liver dysfunction based on other tests, the patient has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
* The patient has, in the investigator's opinion, severe ataxia, neuropathy, balance problems or other medical condition that would interfere the evaluation of the 30s STS test.
* Untreated or undertreated sleep apnoea, in the opinion of the investigator.
* Use of idebenone within 14 days prior to the first dose.
* Patients have a history of unstable or severe pulmonary, immunological, oncological, hepatic disease, renal disease, or another medically significant illness other than PMD or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
* The patient is, in the investigator's opinion, unlikely to comply with the protocol e.g. due to cognitive impairment or is unsuitable for any reason.
* The patient has an immediate family member (defined as family members residing at the same address) who participates in the study.
* Female patients with a positive pregnancy result at Screening or at Baseline.
* A patient cannot participate if they received an investigational drug 30 days or 5 half-lives prior to the Screening Visit (whichever is longer), or plans to use an investigational drug (other than the study intervention) during the study
* Hypersensitivity to the active substance or to any of the excipients or placebo.
* Primary mitochondrial disease nuclear DNA mutations or mutations causing mtDNA destabilisation. Genetic mtDNA variants of uncertain significance, likely pathogenic, or pathogenic mutations with degrees of heteroplasmy below what can be considered to definitely cause PMD.
* General fatigue or muscle weakness due to causes other than mitochondrial disease, in the opinion of the investigator.
* Significant cardiovascular disease (e.g., sustained or symptomatic arrhythmia; dilated heart chambers or reduced function; Mobitz II atrioventricular block or greater) OR abnormal ECG that is clinically significant, as determined by the investigator. Any QTcF \> 450 msec for male patients and \> 470 msec for female patients is exclusionary. In the case of an exclusionary QTcF, the ECG can be repeated twice and the average of 3 QTcF intervals should be used to determine the QTcF eligibility.
* Recent history of unstable disease, inadequately controlled neurological manifestations or not recovered from stroke-like episodes including but not limited to:
1. stroke-like episodes within the last 6 months
2. more than 1 seizure/month within the last 6 months
3. hospitalised for Status Epilepticus within the last 6 months
4. more than 4 days of migraine episodes/month within the last 6 months
* History of inflammatory bowel disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes. Gastroesophageal reflux disease diagnosed by objective endoscopic or radiographic means, and clinically symptomatic at any point over the last 6 months.
* The patient has one or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the Screening Visit, that are of potential risk to the patient's safety, or the patient has, at the Screening Visit:
* estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation \<30 mL/min/1.73 m2
* a serum total bilirubin value \> 1.5 times the upper limit of the reference range unless elevation is related to Gilbert's syndrome and the investigator can rule out any underlying liver dysfunction based on other tests, the patient has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
* a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value \> 2 times the upper limit of the reference range. Values between 2 and 3 times the upper limit of the reference range may be allowed if concomitant to elevation in creatine kinase as long as the investigator can rule out any underlying liver dysfunction based on other tests, the patient has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
* The patient has, in the investigator's opinion, severe ataxia, neuropathy, balance problems or other medical condition that would interfere the evaluation of the 30s STS test.
* Untreated or undertreated sleep apnoea, in the opinion of the investigator.
* Use of idebenone within 14 days prior to the first dose.
* Patients have a history of unstable or severe pulmonary, immunological, oncological, hepatic disease, renal disease, or another medically significant illness other than PMD or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
* The patient is, in the investigator's opinion, unlikely to comply with the protocol e.g. due to cognitive impairment or is unsuitable for any reason.
* The patient has an immediate family member (defined as family members residing at the same address) who participates in the study.
* Female patients with a positive pregnancy result at Screening or at Baseline.
* A patient cannot participate if they received an investigational drug 30 days or 5 half-lives prior to the Screening Visit (whichever is longer), or plans to use an investigational drug (other than the study intervention) during the study
* Hypersensitivity to the active substance or to any of the excipients or placebo.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abliva AB
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amel Karaa, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Grainne Gorman, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Wellcome Centre for Mitochondrial Research, Newcastle University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akron Children's Hospital
Akron, Ohio, United States
Site Status
RECRUITING
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Site Status
RECRUITING
Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel
Brussels, , Belgium
Site Status
RECRUITING
Universitair Ziekenhuis Gent
Ghent, , Belgium
Site Status
RECRUITING
Universitair Ziekenhuis Leuven Gasthuisberg Campus
Leuven, , Belgium
Site Status
RECRUITING
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, , Denmark
Site Status
RECRUITING
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, , France
Site Status
RECRUITING
Hopital Roger Salengro, CHRU de Lille
Lille, , France
Site Status
RECRUITING
Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2
Nice, , France
Site Status
RECRUITING
CHU de NICE - Hôpital Archet 2
Nice, , France
Site Status
RECRUITING
Groupe Hospitalier Pitie-Salpetriere
Paris, , France
Site Status
RECRUITING
IRCCS Institute of Neurological Sciences of Bologna- Universita di Bologna
Bologna, , Italy
Site Status
NOT_YET_RECRUITING
Azienda Ospedaliera Universitaria Gaetano Martino Messina
Messina, , Italy
Site Status
NOT_YET_RECRUITING
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, , Italy
Site Status
NOT_YET_RECRUITING
Azienda Ospedaliero Universitaria Pisana
Pisa, , Italy
Site Status
NOT_YET_RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, , Italy
Site Status
NOT_YET_RECRUITING
CIBERER- IDIBAPS, Faculty of Medicine, University of Barcelona
Barcelona, , Spain
Site Status
RECRUITING
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
COMPLETED
Hospital General Universitario de Catalunya
Barcelona, , Spain
Site Status
RECRUITING
Hospital Universitario 12 de Octubre
Madrid, , Spain
Site Status
RECRUITING
Department of Clinical Neurosciences, Addenbrooke's Hospital
Cambridge, , United Kingdom
Site Status
RECRUITING
University College London Hospitals Nhs Foundation Trust
London, , United Kingdom
Site Status
RECRUITING
Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Belgium
Denmark
France
Italy
Spain
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KL1333 2020-104A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05949294
WITHDRAWN
PHASE1
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT06547216
ENROLLING_BY_INVITATION
PHASE2
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291
RECRUITING
PHASE2
Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy
NCT00004770
COMPLETED
NA
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01089010
COMPLETED
PHASE2
The KHENERGYZE Study
NCT04165239
COMPLETED
PHASE2
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02579239
COMPLETED
PHASE1/PHASE2
Study of SPG302 in Healthy Volunteers and ALS Participants
NCT05882695
COMPLETED
PHASE1
Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
NCT02367014
COMPLETED
PHASE1/PHASE2
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
NCT02528071
TERMINATED
Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis
NCT02286011
UNKNOWN
PHASE1
Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
NCT02805790
COMPLETED
PHASE2
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
NCT05670730
COMPLETED
PHASE1/PHASE2
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
NCT06131983
RECRUITING
PHASE1/PHASE2
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03160898
COMPLETED
PHASE2
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
NCT06244082
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01378676
COMPLETED
PHASE2
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
NCT04641962
TERMINATED
PHASE2
Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies
NCT03513835
COMPLETED
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis
NCT04849065
UNKNOWN
PHASE2
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
NCT02870634
COMPLETED
PHASE1
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
NCT00875446
COMPLETED
PHASE1
Biological Treatment of Amyotrophic Lateral Sclerosis
NCT02193893
UNKNOWN
PHASE1
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
NCT04428775
TERMINATED
PHASE2
Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation
NCT01074359
TERMINATED
PHASE2